Abstract
Genetic variations in the vacuolar protein sorting 10 protein (Vps10p) family have been linked to Alzheimer's disease (AD). Here we demonstrate deposition of fragments from the Vps10p member sortilin at senile plaques (SPs) in aged and AD human cerebrum. Sortilin changes were characterized in postmortem brains with antibodies against the extracellular and intracellular C-terminal domains. The two antibodies exhibited identical labeling in normal human cerebrum, occurring in the somata and dendrites of cortical and hippocampal neurons. The C-terminal antibody also marked extracellular lesions in some aged and all AD cases, appearing as isolated fibrils, mini-plaques, dense-packing or circular mature-looking plaques. Sortilin and β-amyloid (Aβ) deposition were correlated overtly in a region/lamina- and case-dependent manner as analyzed in the temporal lobe structures, with co-localized immunofluorescence seen at individual SPs. However, sortilin deposition rarely occurred around the pia, at vascular wall or in areas with typical diffuse Aβ deposition, with the labeling not enhanced by section pretreatment with heating or formic acid. Levels of a major sortilin fragment ~15 kDa, predicted to derive from the C-terminal region, were dramatically elevated in AD relative to control cortical lysates. Thus, sortilin fragments are a prominent constituent of the extracellularly deposited protein products at SPs in human cerebrum.
Introduction
The hallmark of Alzheimer’s Disease (AD) is the "senile plaque," a complex environment primarily composed of aggregated β-amyloid (Aβ) peptides. However, these plaques also contain a variety of other proteins and cellular debris that reflect the broader "molecular graveyard" of the AD brain. Genetic studies have long linked the Vps10p protein family, which includes sortilin, to AD risk. Sortilin is a multi-functional receptor involved in protein trafficking and cell signaling, but its physical role in AD pathology has remained unclear. This study investigates whether sortilin or its fragments deposit in the extracellular space of the human brain as part of the disease process.
Methods and Validation
The researchers analyzed postmortem brain samples from over 70 cases, including mid-age controls, aged controls, and confirmed AD cases. To ensure the specificity of the findings, antibodies targeting the extracellular N-terminal and intracellular C-terminal domains of sortilin were validated using sortilin knockout (-/-) mice.
Techniques included immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting to measure protein levels and fragment sizes. The team also tested antigen retrieval methods, comparing sortilin's visibility to Aβ after treatment with formic acid and heat.
Key Results
Cellular Localization and Fragment Deposition
In healthy brains, sortilin is concentrated in the somata and dendrites of cortical and hippocampal neurons. Immunofluorescence confirms that antibodies against different domains show identical labeling patterns in normal tissue.
In AD brains, a specific ~15 kDa C-terminal fragment of sortilin was found to deposit extracellularly. This fragment is significantly elevated in AD cortical lysates compared to controls. Interestingly, sortilin fragments exhibit selective pathology: they are prominent in mature neuritic plaques but absent from diffuse plaques and cerebral amyloid angiopathy (CAA) in blood vessel walls.
Correlation with Amyloid Pathology
In the hippocampus, the area occupied by sortilin deposits correlated strongly with Aβ area ($R^2 = 0.932$). Unlike Aβ, which often requires harsh pretreatment to be visualized, sortilin fragments are readily detectable, suggesting they are not as deeply buried or folded as amyloid fibrils.
Discussion and Future Directions
The discovery of sortilin fragments as a major constituent of senile plaques suggests they are specific markers of neuronal and synaptic degeneration. As sortilin is highly concentrated in dendritic spines, its proteolytic cleavage—potentially by enzymes like BACE1 or γ-secretase—and subsequent deposition likely reflect the breakdown of critical survival signaling pathways.
While this study establishes a strong correlation between sortilin deposition and AD, further research is needed to determine if these fragments are active participants in neurotoxicity or simply markers of the disease process. Understanding the functional impact of sortilin loss and fragment accumulation may provide new insights into the mechanisms of cognitive decline in Alzheimer's Disease.
Summary updated